BBA
ANAC

Baker Bros. Advisors’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Baker Bros. Advisors’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,122,375
Closed -$274M – 142
2016
Q1 		$274M Buy
5,122,375
+923,855
+22% +$68.2M 2.89% 10
2015
Q4 		$474M Buy
4,198,520
+63,108
+2% +$6.95M 3.93% 9
2015
Q3 		$487M Buy
4,135,412
+509,914
+14% +$66.6M 4.5% 8
2015
Q2 		$281M Sell
3,625,498
-579,204
-14% -$38M 2.46% 11
2015
Q1 		$243M Hold
4,204,702
– – 2.02% 12
2014
Q4 		$136M Hold
4,204,702
– – 1.38% 13
2014
Q3 		$103M Buy
4,204,702
+956,659
+29% +$19.4M 1.3% 15
2014
Q2 		$57.6M Buy
3,248,043
+152,725
+5% +$2.46M 0.71% 20
2014
Q1 		$61.9M Buy
3,095,318
+595,318
+24% +$11.5M 0.79% 22
2013
Q4 		$42M Buy
2,500,000
+1,623,537
+185% +$22.5M 0.59% 24
2013
Q3 		$9.31M Hold
876,463
– – 0.13% 45
2013
Q2 		$4.9M Buy
+876,463
New +$5.31M 0.1% 48

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Baker Bros. Advisors's ANAC Position: Q2 2016 in Review

Baker Bros. Advisors sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 5,122,375 shares — an estimated $274M sold.

Baker Bros. Advisors first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $487M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Baker Bros. Advisors reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Baker Bros. Advisors sold 5,122,375 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $274M.
  • Baker Bros. Advisors first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Baker Bros. Advisors's ANACOR PHARMACEUTICALS INC COM position peaked at $487M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.